ERBB2 and neoplasm: HER2 protein expression is commonly assessed using immunohistochemistry (IHC), categorized as overexpression (IHC 3+), moderate expression (IHC 2+), or low or ultra-low expression (IHC 1+ or 0) based on the number of stained tumor cells, staining intensity, and completeness of membrane staining.